1-(5-氯-噻吩-2-基)-4,4,4-三氟-丁烷-1,3-二酮 | 326-73-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(5-氯-噻吩-2-基)-4,4,4-三氟-丁烷-1,3-二酮
• 英文名称: 1-(5-chloro-[2]thienyl)-4,4,4-trifluoro-butane-1,3-dione
• 英文别名: 1-(5-Chlor-[2]thienyl)-4,4,4-trifluor-butan-1,3-dion；1-(5-Chlorothiophen-2-yl)-4,4,4-trifluorobutane-1,3-dione
• CAS: 326-73-8
• 化学式: C₈H₄ClF₃O₂S
• mdl: MFCD03420647
• 分子量: 256.633
• InChiKey: UATRNJCOYRSWFT-UHFFFAOYSA-N

物化性质

• 沸点：
  307.3±42.0 °C(Predicted)
• 密度：
  1.519±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  62.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-(5-氯-噻吩-2-基)-4,4,4-三氟-丁烷-1,3-二酮 在 N,N-二甲基甲酰胺 盐酸 、 potassium carbonate 、 三氯氧磷 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.75h， 生成 4-(5-chlorothiophen-2-yl)-2-(4-iodoimidazol-1-yl)-6-trifluoromethylpyrimidine
  参考文献：
  名称：

  WO2008/119689

  摘要：

  公开号：
• 作为产物：
  描述：

  2-乙酰基-5-氯噻酚 、 三氟乙酸乙酯 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 1-(5-氯-噻吩-2-基)-4,4,4-三氟-丁烷-1,3-二酮
  参考文献：
  名称：

  Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:  Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)

  摘要：

  A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC-236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of ii (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.

  DOI：

  10.1021/jm960803q

文献信息

• Control of ectoparasites
  申请人：ELI LILLY AND COMPANY

  公开号：EP0202903A2

  公开（公告）日：1986-11-26

  A series of 1,3-propanediones having a perfluoroalkyl group or a perfluorocycloalkyl group on one carbonyl, and a substituted phenyl or thienyl group on the other, are useful when administered to animals for the control of ectoparasites.

  一系列 1,3-丙二酸酯的一个羰基上有一个全氟烷基或全氟环烷基，另一个羰基上有一个取代的苯基或噻吩基，给动物用药时可用于控制体外寄生虫。
• The Synthesis of Certain Beta-Diketones Containing Perfluoromethyl and Perfluoro-n-propyl Groups
  作者：Lloyd B. Barkley、Robert Levine

  DOI：10.1021/ja01154a037

  日期：1951.10
• Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:  Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1<i>H</i>-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
  作者：Thomas D. Penning、John J. Talley、Stephen R. Bertenshaw、Jeffery S. Carter、Paul W. Collins、Stephen Docter、Matthew J. Graneto、Len F. Lee、James W. Malecha、Julie M. Miyashiro、Roland S. Rogers、D. J. Rogier、Stella S. Yu、Gary D. Anderson、Earl G. Burton、J. Nita Cogburn、Susan A. Gregory、Carol M. Koboldt、William E. Perkins、Karen Seibert、Amy W. Veenhuizen、Yan Y. Zhang、Peter C. Isakson

  DOI：10.1021/jm960803q

  日期：1997.4.1

  A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC-236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of ii (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.
• WO2008/119689
  申请人：——

  公开号：——

  公开（公告）日：——